Business Wire

CA-ANDERSEN-GLOBAL

26.8.2020 13:09:04 CEST | Business Wire | Pressemeddelelse

Del
Andersen forener sin latinamerikanske platform

De latinamerikanske medlemsfirmaer i Andersen Global vil nu operere under navnet ”Andersen”, hvilket styrker organisationens position som en one-stop-shop for skattemæssige og juridiske tjenester globalt. Meddelelsen kommer mindre end to måneder efter, at de europæiske medlemsfirmaer i Andersen Global antog Andersen-navnet.

Andersen Globals medlemsfirmaer i Brasilien, Ecuador, Guatemala, Mexico og Uruguay, der tidligere opererede under navnene, ”Andersen Tax” og ”Andersen Tax & Legal,” har nu Andersen som deres navn sammen med de nye medlemsfirmaer, MODO Law og GSRC i Argentina, der blev medlemsfirmaer i organisationen tidligere på året.

Andersen Global fortsætter med at betragte udvidelse af både sit fodaftryk i Latinamerika og sin nyetablerede platform i Caribien som høje prioriteter. I Latinamerika har den globale organisation også en tilstedeværelse i Chile, Colombia, Costa Rica, El Salvador, Honduras, Nicaragua, Panama, Paraguay og Peru gennem sine samarbejdsfirmaer, og har tilføjet samarbejdsfirmaer i 11 lande i Caribien i løbet af de sidste seks måneder.

”Vores ekspansion er drevet af kundeservice, og vores målsætning er ikke at være det største firma, snarere handler vores fokus om vores engagement i at opbygge et firma, hvor kunder får uovertrufne skattemæssige og juridiske tjenester på en sømløs måde overalt i verden,” sagde bestyrelsesformand for Andersen Global og administrerende direktør for Andersen, Mark Vorsatz. ”Vores organisation er ikke kun dedikeret til vores kunder, men også til at investere i vores medarbejdere og den næste generation. Vi deler alle de samme værdier og den samme vision uanset grænser, og det er kun passende, at dette også afspejles i vores navn.”

Organisationens rejse begyndte i 2002, da 23 tidligere Arthur Andersen-partnere oprettede skattefirmaet WTAS. I 2014 antog det amerikanske medlemsfirma navnet “Andersen Tax” og overgik for nylig til Andersen-navnet i 2019. Den globale organisation er vokset eksponentielt siden etableringen af Andersen Global (tidligere WTAS Global) af det grundlæggende amerikanske medlem Andersen Tax LLC i 2013. Efter lanceringen af sin globale platform i Europa debuterede Andersen Global i Latinamerika i 2015. Regionen er siden vokset til mere end 34 lokaliteter, 1.000 skatte- og juraeksperter, og 90 partnere i dag.

Leonardo Mesquita, regional administrerende direktør for Latinamerika tilføjede, ”Vores organisations fundament er baseret på vores fælles vision om at forblive uafhængige og levere sømløse, synergistiske tjenester til vores kunder globalt. Vi glæder os til at have et navn, der afspejler det, vi allerede ved – vi er ét firma.”

I løbet af det næste år fortsætter medlemsfirmaer globalt med at antage Andersen-navnet, mens Andersen Global fortsætter sin ekspansionsindsats på vigtige markeder, herunder Caribien, Latinamerika, Afrika og Mellemøsten.

Andersen Global er en international sammenslutning af juridisk separate, uafhængige medlemsfirmaer, bestående af skatte- og juraeksperter fra hele verden. Siden oprettelsen i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 6.000 eksperter globalt og er repræsenteret på over 191 lokaliteter via sine medlems- og samarbejdsfirmaer.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye